A Neurosurgical Perspective on Brain Metastases from Renal Cell Carcinoma: Multi-Institutional, Retrospective Analysis

• Published in: Biomedicines Vol. 11; no. 9; p. 2485
• Main Authors: Semenescu, Liliana Eleonora, Tataranu, Ligia Gabriela, Dricu, Anica, Ciubotaru, Gheorghe Vasile, Radoi, Mugurel Petrinel, Rodriguez, Silvia Mara Baez, Kamel, Amira
• Format: Journal Article
• Language: English
• Published: Basel MDPI AG 01-09-2023; MDPI
• Subjects: brain metastases; Cancer therapies; Carcinoma, Renal cell; Care and treatment; Cyclin-dependent kinases; Development and progression; Genes; Growth factors; Hemoglobin; Kidney cancer; Kinases; Medical imaging; Medical prognosis; Medical research; Medical treatment; Medicine, Experimental; Metabolism; Metastases; Metastasis; Mortality; Mutation; Nephrectomy; Nervous system; Neurosurgery; Patients; Proteins; Radiomics; Renal cell carcinoma; Surgery; targeted therapy; Type 2 diabetes; Romania
• ISSN: 2227-9059; 2227-9059
• DOI: 10.3390/biomedicines11092485

Background: While acknowledging the generally poor prognostic features of brain metastases from renal cell carcinoma (BM RCC), it is important to be aware of the fact that neurosurgery still plays a vital role in managing this disease, even though we have entered an era of targeted therapies. Notwithstanding their initial high effectiveness, these agents often fail, as tumors develop resistance or relapse. Methods: The authors of this study aimed to evaluate patients presenting with BM RCC and their outcomes after being treated in the Neurosurgical Department of Clinical Emergency Hospital “Bagdasar-Arseni”, and the Neurosurgical Department of the National Institute of Neurology and Neurovascular Diseases, Bucharest, Romania. The study is based on a thorough appraisal of the patient’s demographic and clinicopathological data and is focused on the strategic role of neurosurgery in BM RCC. Results: A total of 24 patients were identified with BM RCC, of whom 91.6% had clear-cell RCC (ccRCC) and 37.5% had a prior nephrectomy. Only 29.1% of patients harbored extracranial metastases, while 83.3% had a single BM RCC. A total of 29.1% of patients were given systemic therapy. Neurosurgical resection of the BM was performed in 23 out of 24 patients. Survival rates were prolonged in patients who underwent nephrectomy, in patients who received systemic therapy, and in patients with a single BM RCC. Furthermore, higher levels of hemoglobin were associated in our study with a higher number of BMs. Conclusion: Neurosurgery is still a cornerstone in the treatment of symptomatic BM RCC. Among the numerous advantages of neurosurgical intervention, the most important is represented by the quick reversal of neurological manifestations, which in most cases can be life-saving.